Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all
J Viral Hepat
.
2016 Sep;23(9):664-6.
doi: 10.1111/jvh.12550.
Epub 2016 Jun 8.
Authors
J Grebely
1
,
A Litwin
2
,
G J Dore
1
Affiliations
1
The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
2
Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
PMID:
27272285
PMCID:
PMC6868522
DOI:
10.1111/jvh.12550
No abstract available
Keywords:
IFN-free; PWID; drug users; hepatitis C virus; injecting; injection.
Publication types
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Antiviral Agents
Hepacivirus*
Hepatitis C*
Humans
Substance Abuse, Intravenous
Substances
Antiviral Agents
Grants and funding
R01 DA034086/DA/NIDA NIH HHS/United States